Topics

Risk Management Plans: GVP Module V Revision 2 and Its Local Impact in the EU, Upcoming Webinar Hosted by Xtalks

08:30 EST 16 Jan 2020 | PR Web

Risk management plans in the EU have undergone significant changes to address the European Medicines Agency (EMA) Guideline on Good Pharmacovigilance Practices (GVP) Module V Revision 2. In this free webinar, an industry expert will share case studies to illustrate the critical differences resulting from Revision 2 and describe the implications of potentially removing risks from risk management plans. Pharmaceutical professionals will benefit from learning how Revision 2 to GVP Module V will affect nationwide drug approvals.

TORONTO (PRWEB) January 16, 2020

Module V of GVP, which governs Risk Management Plans (RMPs) and Systems, has gone through a significant overhaul with its second revision. One of the most important aspects of this update is the possibility to remove risks from RMPs, provided that it can be demonstrated to the authorities that these are adequately managed. This issue does not always arise with central authorities like the EMA but can affect approvals of local EU authorities as well.

Join Dr. Kosta Cvijovic, EU QPPV from Syneos Health, the only fully integrated biopharmaceutical solution organization, on Thursday, February 6, 2020 at 9am EST (2pm GMT/UK) for a live webinar where attendees will hear:

  • An overview of the current Module V of the GVP
  • A review of changes resulting from Revision 2
  • Exploration of practical applications of Module V through case studies, both when it comes to interactions with the EMA and ANSM
  • Discussion of Benefits and challenges of risk removal and/or adaptation
  • A review of changes to the modular system of the GVP documents

Special focus will be put on data and arguments for risk removal and/or adaptation, the success rate of such an approach, as well as the change in the modular system of the GVP documents which no longer necessarily makes Periodic Safety Update Reports’ (PSURs’)/Periodic Benefit-Risk Evaluation Reports’ (PBRERs’) and RMPs risk sections fully exchangeable.

For more information or to register for this event, visit Risk Management Plans: GVP Module V Revision 2 and Its Local Impact in the EU.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:
Candice Tang
Tel: +1 (416) 977-6555 ext 400
Email: ctang@xtalks.com

For the original version on PRWeb visit: https://www.prweb.com/releases/risk_management_plans_gvp_module_v_revision_2_and_its_local_impact_in_the_eu_upcoming_webinar_hosted_by_xtalks/prweb16840423.htm

NEXT ARTICLE

More From BioPortfolio on "Risk Management Plans: GVP Module V Revision 2 and Its Local Impact in the EU, Upcoming Webinar Hosted by Xtalks"

Quick Search

Relevant Topics

Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...